B
B

Biogen


Wiadomości

EU regulator accepts for review Alzheimer's treatment from Eisai-Biogen

UPDATE 1-EU regulator accepts for review Alzheimer's treatment from Eisai-Biogen Adds background Jan 26 (Reuters) - Japanese drugmaker Eisai Co Ltd 4523.T and Biogen Inc BIIB.O said on Thursday the European Medicines Agency (EMA) had accepted a marketing authorization application for their Alzheimer's disease drug. The drug, lecanemab, which was recently granted accelerated approval in the United States, is an antibody that has been shown to remove sticky deposits of a protein called amyloid bet
B

EU regulator accepts for review Alzheimer's treatment from Eisai-Biogen

UPDATE 1-EU regulator accepts for review Alzheimer's treatment from Eisai-Biogen Adds background Jan 26 (Reuters) - Japanese drugmaker Eisai Co Ltd 4523.T and Biogen Inc BIIB.O said on Thursday the European Medicines Agency (EMA) had accepted a marketing authorization application for their Alzheimer's disease drug. The drug, lecanemab, which was recently granted accelerated approval in the United States, is an antibody that has been shown to remove sticky deposits of a protein called amyloid bet
B

EU regulator accepts Biogen-Eisai's Alzheimer's treatment lecanemab for review

EU regulator accepts Biogen-Eisai's Alzheimer's treatment lecanemab for review Jan 26 (Reuters) - Eisai Co Ltd 4523.T and Biogen Inc BIIB.O said on Thursday the European Medicines Agency (EMA) had accepted a marketing authorization application for their Alzheimer's disease drug for review. The drug, lecanemab, was recently granted accelerated approval in the United States.
B

Lonza to buy back $2.17 bln worth of shares, backs mid-term growth

UPDATE 2-Lonza to buy back $2.17 bln worth of shares, backs mid-term growth Adds background on investments, headwinds By Ludwig Burger and Tristan Chabba Jan 25 (Reuters) - Lonza LONN.S on Wednesday said it will buy back shares worth 2 billion Swiss francs ($2.17 billion), despite an expected drop in annual margins, as the Swiss drug contract manufacturer backed its growth prospects for the near future.
B
L

Lonza full-year earnings edge market expectations

Lonza full-year earnings edge market expectations Jan 25 (Reuters) - Swiss drug contract manufacturer Lonza LONN.S reported full-year core earnings above expectations, as demand from biopharmaceutical companies remained strong throughout the year. The Basel-based firm reported core EBITDA, or earnings before interest, taxes, depreciation, amortisation and special items, of 2.0 billion Swiss francs ($2.17 billion), up 19.8%.
B
L

Eli Lilly Alzheimer's drug setback extends rival Biogen's lead

UPDATE 1-Eli Lilly Alzheimer's drug setback extends rival Biogen's lead Adds Biogen share movement, background, updates Eli Lilly shares Jan 20 (Reuters) - The U.S. health regulator's rejection of accelerated approval for Eli Lilly and Co's LLY.N Alzheimer's disease drug extends the market lead for rivals Eisai and Biogen's treatment by months, analysts said.
B

U.S. STOCKS Netflix, PagerDuty, Proterra

BUZZ-U.S. STOCKS ON THE MOVE-Netflix, PagerDuty, Proterra Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The S&P 500 and the Nasdaq rose on Friday after Netflix kicked off the earnings season for growth stocks on an upbeat note, while Google parent Alphabet gained on news of job cuts.
A
B
B
B
C
D
G
H
N
S
T
U
T
T
U
U
R

U.S. STOCKS Biogen, Wayfair, Costco

BUZZ-U.S. STOCKS ON THE MOVE-Biogen, Wayfair, Costco Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Nasdaq futures rose on Friday, after Netflix kicked off the earnings season for the growth sector on a positive note, but worries about a U.S.
A
B
B
C
D
F
G
H
N
S
T
T
U
R

Eli Lilly Alzheimer's drug setback extends rival Biogen's lead - analysts

Eli Lilly Alzheimer's drug setback extends rival Biogen's lead - analysts Jan 20 (Reuters) - The U.S. health regulator's rejection of accelerated approval for Eli Lilly and Co's LLY.N Alzheimer's disease drug extends the market lead for rivals Eisai and Biogen's treatment by months, analysts said. The U.S. Food and Drug Administration (FDA) declined to approve donanemab because Lilly had not submitted data from enough patients who were treated for at least a year, the drugmaker said late Thursda
B

Eli Lilly says U.S. FDA rejects accelerated approval for Alzheimer's drug

UPDATE 3-Eli Lilly says U.S. FDA rejects accelerated approval for Alzheimer's drug Adds neurologist comments, patient advocacy group comment By Deena Beasley Jan 19 (Reuters) - Eli Lilly and Co LLY.N on Thursday said the U.S. Food and Drug Administration had rejected accelerated approval of its experimental Alzheimer's drug because it had not submitted enough trial data from patients who were treated for at least a year.
B

U.S. STOCKS Apple, Surmodics, Domino's

BUZZ-U.S. STOCKS ON THE MOVE-Apple, Surmodics, Domino's Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 U.S. stock indexes were set to open lower on Thursday as recession worries crept into the foreground of the earnings season, while shares of Procter & Gamble fell as it warned of cost pressures.
A
A
A
B
G
H
J
M
T
T
U
E
R

Eisai files for approval of Alzheimer's drug in Japan

(Updates with background) Jan 16 (Reuters) - Japanese drugmaker Eisai Co Ltd 4523.T said on Monday it had submitted a marketing authorisation application in Japan for its Alzheimer's drug lecanemab, which was recently granted accelerated approval in the United States. The drug, developed in partnership with Biogen Inc BIIB.O , is an antibody that has been shown to remove sticky deposits of a protein called amyloid beta from the brains of those in the early stages of the mind-wasting disease.
B

Wall St rallies as jobs, services data calm rate hike worries

(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window) * U.S. December payrolls up 223,000 vs est 200,000 * Dec. non-manufacturing PMI 49.6 vs November's 56.5 read * Biogen closes higher as FDA approves Alzheimer's drug * Indexes up: Dow 2.13%, S&P 2.28%, Nasdaq 2.56% By Sinéad Carew and Ankika Biswas Jan 6 (Reuters) - Wall Street's main indexes all gained more than 2% on Friday after December payrolls expanded more than expected even as wag
B
B
C
P
U
U

Wall Street ends sharply higher after Powell comments

(For a Reuters live blog on U.S., UK and European stock markets, click or type LIVE/ in a news window) * Tesla rises as sales in China nearly double in November - data * U.S. private payrolls growth slows in November - ADP * Powell says Fed could scale back rate hikes in December * Indexes end: S&P 500 +3.09%, Nasdaq +4.41%, Dow +2.18% (Updates with detail on S&P 500 moving average, graphics) By Noel Randewich and Shreyashi Sanyal Nov 30 (Reuters) - Wall Street ended sharply higher on Wednesday
A
B
M
N
T
U
U

Wall Street ends sharply higher after Powell comments

(For a Reuters live blog on U.S., UK and European stock markets, click or type LIVE/ in a news window) * Tesla rises as sales in China nearly double in November - data * U.S. private payrolls growth slows in November - ADP * Powell says Fed could scale back rate hikes in December * Indexes end: S&P 500 +3.09%, Nasdaq +4.41%, Dow +2.18% (Updates with details following close of trading session) By Noel Randewich and Shreyashi Sanyal Nov 30 (Reuters) - Wall Street ended sharply higher on Wednesday
A
B
M
N
T
U
U

Wall Street ends sharply higher after Powell comments

(For a Reuters live blog on U.S., UK and European stock markets, click or type LIVE/ in a news window) * Tesla rises as sales in China nearly double in November - data * U.S. private payrolls growth slows in November - ADP * Powell says Fed could scale back rate hikes in December (Updates with details at close of trading session) By Noel Randewich and Shreyashi Sanyal Nov 30 (Reuters) - Wall Street ended sharply higher on Wednesday after Federal Reserve Chair Jerome Powell said the central bank
A
B
N
T
U
U

Wall Street rallies after Powell eyes slower rate hikes

(For a Reuters live blog on U.S., UK and European stock markets, click or type LIVE/ in a news window) * Tesla up as sales in China nearly double in November - data * U.S. private payrolls growth slows in November - ADP * S&P 500 +1.71%, Nasdaq +2.87%, Dow +0.93% By Noel Randewich and Shreyashi Sanyal Nov 30 (Reuters) - Wall Street jumped on Wednesday after Federal Reserve Chair Jerome Powell said the central bank might scale back the pace of its interest rate hikes as soon as December.
A
B
N
T
U
U

New York Times business news - Nov 30

Nov 30 (Reuters) - The following are the top stories on the New York Times business pages. Reuters has not verified these stories and does not vouch for their accuracy. - Eisai Co Ltd 4523.T and Biogen Inc BIIB.O released new data Tuesday evening, offering the first detailed look at the effects of the experimental Alzheimer's drug, lecanemab, suggesting that the treatment slowed cognitive decline for people in the early stages of the disease but also caused some patients to experience brain swel
B

Wall Street Journal - Nov 30

Nov 30 (Reuters) - The following are the top stories in the Wall Street Journal. Reuters has not verified these stories and does not vouch for their accuracy. - Airbnb Inc ABNB.O is launching a listing service for rental apartments with some of the biggest landlords and property managers in the country, a bid to expand its business in multifamily buildings where owners often shun short-term rentals.
A
B
K

Wall Street ends down sharply, hit by Apple and China worries

(For a Reuters live blog on U.S., UK and European stock markets, click or type LIVE/ in a news window) * Cyber Monday spending to hit $11.6 bln - report * Crypto shares fall on BlockFi bankruptcy filing * Biogen down after death in Alzheimer drug trial * Indexes end: S&P 500 -1.54%, Nasdaq -1.58%, Dow -1.45% (Updates with details following end of trading session) By Ankika Biswas and Noel Randewich Nov 28 (Reuters) - U.S.
A
A
B
M
N
T
U
U



Warunki

Popularne aktywa

Wyłączenie odpowiedzialności: Każdy z podmiotów należących do XM Group świadczy usługę polegającą wyłącznie na realizacji zleceń i dostępie do naszej internetowej platformy transakcyjnej, umożliwiając danej osobie przeglądanie i/lub korzystanie z treści dostępnych na stronie lub za jej pośrednictwem, co nie ma na celu zmiany lub rozszerzenia tego zakresu, ani nie zmienia i nie rozszerza go. Taki dostęp i korzystanie z niego podlegają w każdej chwili: (i) Warunkom umowy, (ii) Ostrzeżeniom o ryzyku i (iii) Pełnemu wyłączeniu odpowiedzialności. Treści te są zatem podawane wyłącznie jako informacje ogólne. W szczególności należy pamiętać, że treści zawarte na naszej internetowej platformie transakcyjnej nie stanowią oferty ani zaproszenia do zawarcia jakichkolwiek transakcji na rynkach finansowych. Transakcje na każdym rynku finansowym wiążą się ze znacznym poziomem ryzyka dla twojego kapitału.

Wszystkie materiały publikowane na naszej internetowej platformie transakcyjnej są przeznaczone wyłącznie do celów edukacyjnych/informacyjnych i nie zawierają – i nie powinny być uważane za zawierające – porad ani rekomendacji dotyczących finansów, inwestycji, podatków lub transakcji, zapisu naszych cen transakcyjnych, ani też oferty lub zaproszenia do transakcji na jakichkolwiek instrumentach lub niezamówionych promocji finansowych.

Wszelkie treści pochodzące od podmiotów trzecich, jak i treści przygotowane przez XM, takie jak opinie, wiadomości, badania, analizy, ceny i inne informacje lub linki do stron podmiotów trzecich zawarte na tej stronie internetowej są udostępniane na zasadzie „tak, jak jest” jako ogólny komentarz rynkowy i nie stanowią porady inwestycyjnej. W zakresie, w jakim jakakolwiek treść jest interpretowana jako badania inwestycyjne, należy zauważyć i zaakceptować, że treść ta nie była przeznaczona i nie została przygotowana zgodnie z wymogami prawnymi mającymi na celu promowanie niezależności badań inwestycyjnych i jako taka byłaby uważana za komunikat marketingowy w świetle odpowiednich przepisów prawnych i regulacji. Upewnij się, że przeczytałeś(-aś) i rozumiesz nasze dokumenty Powiadomienie o zależnych badaniach inwestycyjnych oraz Ostrzeżenie o ryzyku, dotyczące powyższych informacji, do których można uzyskać dostęp tutaj.

Korzystamy z plików cookie, aby zapewnić użytkownikom optymalne warunki korzystania z naszej strony internetowej. Dowiedz się więcej lub zmień swoje ustawienia plików cookie.

Ostrzeżenie o ryzyku: Twój kapitał jest zagrożony. Produkty z zastosowaniem dźwigni mogą nie być odpowiednie dla każdego inwestora. Zapoznaj się z Ujawnieniem ryzyka.